share_log

Aditxt | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions

Aditxt | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions

Aditxt | 425：募資說明/企業合併公告
美股SEC公告 ·  2024/09/06 15:21

Moomoo AI 已提取核心訊息

Aditxt, Inc., a biotech company, has announced an amendment to its merger agreement with Evofem Biosciences, Inc. The amendment, detailed in a Current Report on Form 8-K filed with the SEC, revises the terms of the company's equity investments in Evofem. The third equity investment date has been changed from September 6, 2024, to September 30, 2024, with the investment amount reduced from $2 million to $1.5 million. Additionally, the fourth equity investment date has been extended from September 30, 2024, to October 31, 2024, with the investment amount increased from $1 million to $1.5 million. This follows a series of agreements and amendments starting from December 11, 2023, when Aditxt initially entered into a merger agreement with Evofem. The merger will result in Evofem becoming a wholly owned subsidiary of Aditxt. The...Show More
Aditxt, Inc., a biotech company, has announced an amendment to its merger agreement with Evofem Biosciences, Inc. The amendment, detailed in a Current Report on Form 8-K filed with the SEC, revises the terms of the company's equity investments in Evofem. The third equity investment date has been changed from September 6, 2024, to September 30, 2024, with the investment amount reduced from $2 million to $1.5 million. Additionally, the fourth equity investment date has been extended from September 30, 2024, to October 31, 2024, with the investment amount increased from $1 million to $1.5 million. This follows a series of agreements and amendments starting from December 11, 2023, when Aditxt initially entered into a merger agreement with Evofem. The merger will result in Evofem becoming a wholly owned subsidiary of Aditxt. The report also includes forward-looking statements and a cautionary note indicating that the merger is subject to stockholder approval and other closing conditions. The company has also indicated that it will file a Proxy Statement / Registration Statement with the SEC, which will include a proxy statement/prospectus for the stockholders of Aditxt.
Aditxt公司，一家生物技術公司，已宣佈修訂其與evofem biosciences公司的合併協議。根據提交給證券交易委員會的Form 8-k文件中詳細說明，該修訂修改了公司對Evofem的股權投資條款。第三輪股權投資日期從2024年9月6日更改爲2024年9月30日，投資金額從200萬美元降低至150萬美元。此外，第四輪股權投資日期從2024年9月30日延長至2024年10月31日，投資金額從100萬美元增加至150萬美元。此前，從2023年12月11日開始，Aditxt與Evofem最初簽署了一系列協議和修訂。合併將導致Evofem成爲Aditxt的全資子公司。該報告還包含了前瞻性聲明和一份警示說明，指出該合併還需股東批准和其他關閉條件。該公司還表示將向證券交易委員會提交一份代理聲明/註冊聲明，其中將包括Aditxt股東的代理聲明/招股說明書。
Aditxt公司，一家生物技術公司，已宣佈修訂其與evofem biosciences公司的合併協議。根據提交給證券交易委員會的Form 8-k文件中詳細說明，該修訂修改了公司對Evofem的股權投資條款。第三輪股權投資日期從2024年9月6日更改爲2024年9月30日，投資金額從200萬美元降低至150萬美元。此外，第四輪股權投資日期從2024年9月30日延長至2024年10月31日，投資金額從100萬美元增加至150萬美元。此前，從2023年12月11日開始，Aditxt與Evofem最初簽署了一系列協議和修訂。合併將導致Evofem成爲Aditxt的全資子公司。該報告還包含了前瞻性聲明和一份警示說明，指出該合併還需股東批准和其他關閉條件。該公司還表示將向證券交易委員會提交一份代理聲明/註冊聲明，其中將包括Aditxt股東的代理聲明/招股說明書。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Portage Biotech
    PRTG
    -- 9.600
    萊斯康製藥
    LXRX
    -- 0.571
    DBV Technologies
    DBVT
    -- 6.200
    NeOnc Technologies
    NTHI
    -- 16.550
    Alumis
    ALMS
    -- 5.640
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    中概股財報季火熱：驚喜盈利能否延續漲勢？
    1. 哪些行業可能成為本輪財報季的市場焦點？ 2. 在政府強調科技創新和可持續發展的背景下，你認為哪些行業具有最大的增長潜力？ 展开
    中國兩會：會議前後股票價格變動的關鍵要點